Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14043918 | 0.86 | GAA (0.48) | P2RX3P2RX2TAAR1GAAPOLB | |
| SCHEMBL13683170 | 0.83 | ALDH1A1 (0.50) | P2RX3P2RX2TAAR1LPAR1ALDH1A1 | |
| SCHEMBL16200311 | 0.83 | MAPT (0.42) | LMNATAAR1ALDH1A1GAANPC1 | |
| SCHEMBL13178799 | 0.80 | KMT2A (0.55) | ALDH1A1GAAPOLB | |
| SCHEMBL13178789 | 0.80 | MTNR1A (0.49) | LMNALPAR1ALDH1A1 | |
| SCHEMBL13184317 | 0.80 | MEN1 (0.47) | P2RX3P2RX2ALDH1A1GAAPOLB | |
| SCHEMBL13683163 | 0.79 | THRB (0.46) | P2RX3P2RX2TAAR1LPAR1ALDH1A1 | |
| SCHEMBL13178788 | 0.79 | TAAR1 (0.49) | P2RX3P2RX2TAAR1GAANPC1 | |
| SCHEMBL13178792 | 0.77 | CYP2D6 (0.44) | P2RX3P2RX2LPAR1ALDH1A1 | |
| SCHEMBL13178790 | 0.76 | SLC6A4 (0.40) | P2RX3P2RX2TAAR1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | P2RX3 509/4885P2RX2 614/4885LMNA 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.